I'm not putting my
life on pause for
menopause."
that reduced hot flashes and night sweats
and improved vaginal symptoms1-3
I'm not putting my
life on pause for
menopause."
that reduced hot flashes and night sweats
and improved vaginal symptoms1-3
I'm not putting my
life on pause for
menopause."
that reduced hot flashes and
night sweats and improved
vaginal symptoms1-3
Femring is a soft, flexible vaginal ring that releases estrogen for 3 months1
- The estrogen in Femring is the same estrogen produced in
the ovaries1,4
One ring of Femring reduced hot flashes, night sweats, and vaginal symptoms for 3 months5
- Women had a positive experience with Femring6
- 90% of women said they would continue using Femring
- 96% said they would recommend it to a friend
- Every-3-month dosing1 fits into busy women's lives
Femring is a soft, flexible vaginal ring that releases estrogen for 3 months1
- The estrogen in Femring is the same estrogen produced in the ovaries1,4
One ring of Femring reduced hot flashes, night sweats, and vaginal symptoms for 3 months5
- Women had a positive experience with Femring6
- 90% of women said they would continue using Femring
- 96% said they would recommend it to a friend
- Every-3-month dosing1 fits into busy women's lives
Femring is a soft, flexible vaginal ring that releases estrogen for 3 months1
- The estrogen in Femring is the same estrogen produced in the ovaries1,4
One ring of Femring reduced hot flashes, night sweats, and vaginal symptoms for 3 months5
- Women had a positive experience with Femring6
- 90% of women said they would continue using Femring
- 96% said they would recommend it to a friend
- Every-3-month dosing1 fits into busy women's lives
If you are a woman starting
on Femring
Download a helpful treatment guide, with
steps for inserting and removing Femring
If you are a woman starting on Femring
If you are a woman starting on Femring
Download a helpful treatment guide, with steps for inserting and removing Femring
Download a helpful treatment guide, with steps for inserting and removing Femring
IMPORTANT SAFETY INFORMATION AND INDICATION
The most important information you should know about Femring® (estradiol acetate vaginal ring) (an estrogen hormone)
- Using estrogen-alone may increase your chance of getting cancer of the uterus (womb). Report any unusual vaginal bleeding right away while you are using Femring. Vaginal bleeding after menopause may be a warning sign of cancer of the uterus (womb). Your healthcare provider should check any unusual vaginal bleeding to find out the cause.
- Do not use estrogen-alone to prevent heart disease, heart attacks, strokes or dementia (decline in brain function).
- Using estrogen-alone may increase your chances of getting strokes or blood clots.
- Using estrogen-alone may increase your chance of getting dementia, based on a study of women 65 years of age or older.
- Do not use estrogens with progestins to prevent heart disease, heart attacks, strokes or dementia.
- Using estrogens with progestins may increase your chances of getting heart attacks, strokes, breast cancer, or blood clots.
- Using estrogens with progestins may increase your chance of getting dementia, based on a study of women 65 years of age or older.
- You and your healthcare provider should talk regularly about whether you still need treatment with Femring.
Femring is a prescription vaginal ring that contains estradiol (an estrogen hormone). Femring should be removed after 90 days of continuous use. If you and your healthcare provider decide you should continue using Femring, a new ring can be inserted in your vagina.
Femring is used after menopause to reduce moderate to severe hot flushes and treat moderate to severe menopausal changes in and around the vagina.
Do not start using Femring if you have unusual vaginal bleeding; currently have or have had certain cancers, blood clots, or liver problems; had a stroke or heart attack; have been diagnosed with a bleeding disorder; are allergic to Femring or any of its ingredients; or think you might be pregnant.
Before you use Femring, tell your healthcare provider if you have any unusual vaginal bleeding, have any problems with your vagina or cervix (lower end of your womb), have any other medical conditions, are going to have surgery or will be on bed rest, or are breastfeeding. Also tell your healthcare provider about all the medicines you take, including prescription and nonprescription medicines, vitamins and herbal supplements.
Estrogens increase the risk of gallbladder disease. Discontinue estrogen if loss of vision, pancreatitis, or liver problems occur. If you take thyroid medication, consult your healthcare provider, as use of estrogens may change the amount needed.
Serious, but less common side effects include heart attack, stroke, blood clots, dementia, breast cancer, cancer of the lining of the uterus (womb), cancer of the ovary, high blood pressure, high blood sugar, gallbladder disease, liver problems, changes in your thyroid hormone levels, and enlargement of benign tumors of the uterus (“fibroids”).
Less serious, but common side effects include headache; breast tenderness or pain; irregular vaginal bleeding or spotting; stomach or abdominal cramps; bloating, nausea and vomiting; hair loss; fluid retention; vaginal yeast infection; and reactions from inserting Femring such as burning, irritation, and itching.
Call your healthcare provider right away if you have any of the following warning signs, or any other unusual symptoms that concern you: new breast lumps, unusual vaginal bleeding, changes in vision or speech, sudden new severe headaches, severe pains in your chest or legs with or without shortness of breath, weakness and fatigue.
For more information, talk with your healthcare provider.
You are encouraged to report negative side effects of prescription drugs to Millicent Pharma at 1-877-810-2101 or to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Please see the full Prescribing Information, including BOXED WARNING, Patient Information, and Instructions for Use.
References: 1. Femring® [package insert]. East Hanover, NJ: Millicent Pharma Ltd; 2018. 2. EstroGel [package insert]. Hendon, VA: Ascend Therapeutics US LLC; 2017. 3. CombiPatch [package insert]. Miami, FL: Noven Pharmaceuticals Inc; 2017. 4. Nichols KC, Schenkel L, Benson H. 17β-estradiol for postmenopausal estrogen replacement therapy. Obstet Gynecol Surv. 1984;39(4):230-245. 5. Speroff L. Efficacy and tolerability of a novel estradiol vaginal ring for relief of menopausal symptoms. Obstet Gynecol. 2003;102(4):823-834. 6. Data on file. Millicent Pharma Ltd.
Femring is a registered trademark and the Millicent Pharma logo is a trademark of Millicent Pharma Limited.
IMPORTANT SAFETY INFORMATION AND INDICATION
The most important information you should know about Femring® (estradiol acetate vaginal ring) (an estrogen hormone)
- Using estrogen-alone may increase your chance of getting cancer of the uterus (womb). Report any unusual vaginal bleeding right away while you are using Femring. Vaginal bleeding after menopause may be a warning sign of cancer of the uterus (womb). Your healthcare provider should check any unusual vaginal bleeding to find out the cause.
- Do not use estrogen-alone to prevent heart disease, heart attacks, strokes or dementia (decline in brain function).
- Using estrogen-alone may increase your chances of getting strokes or blood clots.
- Using estrogen-alone may increase your chance of getting dementia, based on a study of women 65 years of age or older.
- Do not use estrogens with progestins to prevent heart disease, heart attacks, strokes or dementia.
- Using estrogens with progestins may increase your chances of getting heart attacks, strokes, breast cancer, or blood clots.
- Using estrogens with progestins may increase your chance of getting dementia, based on a study of women 65 years of age or older.
- You and your healthcare provider should talk regularly about whether you still need treatment with Femring.
Femring is a prescription vaginal ring that contains estradiol (an estrogen hormone). Femring should be removed after 90 days of continuous use. If you and your healthcare provider decide you should continue using Femring, a new ring can be inserted in your vagina.
Femring is used after menopause to reduce moderate to severe hot flushes and treat moderate to severe menopausal changes in and around the vagina.
Do not start using Femring if you have unusual vaginal bleeding; currently have or have had certain cancers, blood clots, or liver problems; had a stroke or heart attack; have been diagnosed with a bleeding disorder; are allergic to Femring or any of its ingredients; or think you might be pregnant.
Before you use Femring, tell your healthcare provider if you have any unusual vaginal bleeding, have any problems with your vagina or cervix (lower end of your womb), have any other medical conditions, are going to have surgery or will be on bed rest, or are breastfeeding. Also tell your healthcare provider about all the medicines you take, including prescription and nonprescription medicines, vitamins and herbal supplements.
Estrogens increase the risk of gallbladder disease. Discontinue estrogen if loss of vision, pancreatitis, or liver problems occur. If you take thyroid medication, consult your healthcare provider, as use of estrogens may change the amount needed.
Serious, but less common side effects include heart attack, stroke, blood clots, dementia, breast cancer, cancer of the lining of the uterus (womb), cancer of the ovary, high blood pressure, high blood sugar, gallbladder disease, liver problems, changes in your thyroid hormone levels, and enlargement of benign tumors of the uterus (“fibroids”).
Less serious, but common side effects include headache; breast tenderness or pain; irregular vaginal bleeding or spotting; stomach or abdominal cramps; bloating, nausea and vomiting; hair loss; fluid retention; vaginal yeast infection; and reactions from inserting Femring such as burning, irritation, and itching.
Call your healthcare provider right away if you have any of the following warning signs, or any other unusual symptoms that concern you: new breast lumps, unusual vaginal bleeding, changes in vision or speech, sudden new severe headaches, severe pains in your chest or legs with or without shortness of breath, weakness and fatigue.
For more information, talk with your healthcare provider.
You are encouraged to report negative side effects of prescription drugs to Millicent Pharma at 1-877-810-2101 or to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Please see the full Prescribing Information, including BOXED WARNING, Patient Information, and Instructions for Use.
References: 1. Femring® [package insert]. East Hanover, NJ: Millicent Pharma Ltd; 2018. 2. EstroGel [package insert]. Hendon, VA: Ascend Therapeutics US LLC; 2017. 3. CombiPatch [package insert]. Miami, FL: Noven Pharmaceuticals Inc; 2017. 4. Nichols KC, Schenkel L, Benson H. 17β-estradiol for postmenopausal estrogen replacement therapy. Obstet Gynecol Surv. 1984;39(4):230-245. 5. Speroff L. Efficacy and tolerability of a novel estradiol vaginal ring for relief of menopausal symptoms. Obstet Gynecol. 2003;102(4):823-834. 6. Data on file. Millicent Pharma Ltd.
Femring is a registered trademark and the Millicent Pharma logo is a trademark of Millicent Pharma Limited.
IMPORTANT SAFETY INFORMATION AND INDICATION
The most important information you should know about Femring® (estradiol acetate vaginal ring) (an estrogen hormone)
- Using estrogen-alone may increase your chance of getting cancer of the uterus (womb). Report any unusual vaginal bleeding right away while you are using Femring. Vaginal bleeding after menopause may be a warning sign of cancer of the uterus (womb). Your healthcare provider should check any unusual vaginal bleeding to find out the cause.
- Do not use estrogen-alone to prevent heart disease, heart attacks, strokes or dementia (decline in brain function).
- Using estrogen-alone may increase your chances of getting strokes or blood clots.
- Using estrogen-alone may increase your chance of getting dementia, based on a study of women 65 years of age or older.
- Do not use estrogens with progestins to prevent heart disease, heart attacks, strokes or dementia.
- Using estrogens with progestins may increase your chances of getting heart attacks, strokes, breast cancer, or blood clots.
- Using estrogens with progestins may increase your chance of getting dementia, based on a study of women 65 years of age or older.
- You and your healthcare provider should talk regularly about whether you still need treatment with Femring.
Femring is a prescription vaginal ring that contains estradiol (an estrogen hormone). Femring should be removed after 90 days of continuous use. If you and your healthcare provider decide you should continue using Femring, a new ring can be inserted in your vagina.
Femring is used after menopause to reduce moderate to severe hot flushes and treat moderate to severe menopausal changes in and around the vagina.
Do not start using Femring if you have unusual vaginal bleeding; currently have or have had certain cancers, blood clots, or liver problems; had a stroke or heart attack; have been diagnosed with a bleeding disorder; are allergic to Femring or any of its ingredients; or think you might be pregnant.
Before you use Femring, tell your healthcare provider if you have any unusual vaginal bleeding, have any problems with your vagina or cervix (lower end of your womb), have any other medical conditions, are going to have surgery or will be on bed rest, or are breastfeeding. Also tell your healthcare provider about all the medicines you take, including prescription and nonprescription medicines, vitamins and herbal supplements.
Estrogens increase the risk of gallbladder disease. Discontinue estrogen if loss of vision, pancreatitis, or liver problems occur. If you take thyroid medication, consult your healthcare provider, as use of estrogens may change the amount needed.
Serious, but less common side effects include heart attack, stroke, blood clots, dementia, breast cancer, cancer of the lining of the uterus (womb), cancer of the ovary, high blood pressure, high blood sugar, gallbladder disease, liver problems, changes in your thyroid hormone levels, and enlargement of benign tumors of the uterus (“fibroids”).
Less serious, but common side effects include headache; breast tenderness or pain; irregular vaginal bleeding or spotting; stomach or abdominal cramps; bloating, nausea and vomiting; hair loss; fluid retention; vaginal yeast infection; and reactions from inserting Femring such as burning, irritation, and itching.
Call your healthcare provider right away if you have any of the following warning signs, or any other unusual symptoms that concern you: new breast lumps, unusual vaginal bleeding, changes in vision or speech, sudden new severe headaches, severe pains in your chest or legs with or without shortness of breath, weakness and fatigue.
For more information, talk with your healthcare provider.
You are encouraged to report negative side effects of prescription drugs to Millicent Pharma at 1-877-810-2101 or to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Please see the full Prescribing Information, including BOXED WARNING, Patient Information, and Instructions for Use.
References: 1. Femring® [package insert]. East Hanover, NJ: Millicent Pharma Ltd; 2018. 2. EstroGel [package insert]. Hendon, VA: Ascend Therapeutics US LLC; 2017. 3. CombiPatch [package insert]. Miami, FL: Noven Pharmaceuticals Inc; 2017. 4. Nichols KC, Schenkel L, Benson H. 17β-estradiol for postmenopausal estrogen replacement therapy. Obstet Gynecol Surv. 1984;39(4):230-245. 5. Speroff L. Efficacy and tolerability of a novel estradiol vaginal ring for relief of menopausal symptoms. Obstet Gynecol. 2003;102(4):823-834. 6. Data on file. Millicent Pharma Ltd.
Femring is a registered trademark and the Millicent Pharma logo is a trademark of Millicent Pharma Limited.
Femring® is a registered tradmark of Millicent Pharma Limited.
The Millicent Pharma logo is a registered trademark of Millicent Pharma Limited.
© 2024, Millicent Pharma Ltd. All rights reserved. 03/2024
FEM012R1
Femring® is a registered tradmark of Millicent Pharma Limited.
The Millicent Pharma logo is a registered trademark of Millicent Pharma Limited.
© 2024, Millicent Pharma Ltd. All rights reserved. 03/2024
FEM012R1